Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
Apellis Pharmaceuticals (Nasdaq: APLS) has announced its upcoming participation at the TD Cowen 45th Annual Health Care Conference. The presentation is scheduled for Monday, March 3, 2025, at 10:30 a.m. ET.
The company will provide a live webcast of the conference presentation, which will be accessible through the 'Events and Presentations' page in the 'Investors and Media' section of Apellis' website. Interested parties who cannot attend the live presentation will have access to a replay of the webcast for approximately 90 days after the event.
Apellis Pharmaceuticals (Nasdaq: APLS) ha annunciato la sua prossima partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen. La presentazione è programmata per lunedì 3 marzo 2025, alle 10:30 ET.
La società fornirà una diretta streaming della presentazione della conferenza, che sarà accessibile attraverso la pagina 'Eventi e Presentazioni' nella sezione 'Investitori e Media' del sito web di Apellis. Le parti interessate che non possono partecipare alla presentazione dal vivo avranno accesso a una registrazione della diretta per circa 90 giorni dopo l'evento.
Apellis Pharmaceuticals (Nasdaq: APLS) ha anunciado su próxima participación en la 45ª Conferencia Anual de Salud de TD Cowen. La presentación está programada para el lunes 3 de marzo de 2025, a las 10:30 a.m. ET.
La empresa ofrecerá una transmisión en vivo de la presentación de la conferencia, que será accesible a través de la página 'Eventos y Presentaciones' en la sección 'Inversores y Medios' del sitio web de Apellis. Las partes interesadas que no puedan asistir a la presentación en vivo tendrán acceso a una repetición de la transmisión durante aproximadamente 90 días después del evento.
Apellis Pharmaceuticals (Nasdaq: APLS)는 TD Cowen 제45회 연례 헬스케어 컨퍼런스에 참가할 예정이라고 발표했습니다. 발표는 2025년 3월 3일 월요일 오전 10시 30분 ET로 예정되어 있습니다.
회사는 컨퍼런스 발표의 라이브 웹캐스트를 제공하며, 이는 Apellis 웹사이트의 '투자자 및 미디어' 섹션의 '이벤트 및 발표' 페이지를 통해 접근할 수 있습니다. 라이브 발표에 참석할 수 없는 이해관계자는 이벤트 후 약 90일 동안 웹캐스트 재생을 이용할 수 있습니다.
Apellis Pharmaceuticals (Nasdaq: APLS) a annoncé sa prochaine participation à la 45ème Conférence Annuelle sur la Santé de TD Cowen. La présentation est prévue pour le lundi 3 mars 2025, à 10h30 ET.
La société proposera un webinaire en direct de la présentation de la conférence, qui sera accessible via la page 'Événements et Présentations' dans la section 'Investisseurs et Médias' du site web d'Apellis. Les parties intéressées qui ne peuvent pas assister à la présentation en direct auront accès à un replay du webinaire pendant environ 90 jours après l'événement.
Apellis Pharmaceuticals (Nasdaq: APLS) hat seine bevorstehende Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt. Die Präsentation ist für Montag, den 3. März 2025, um 10:30 Uhr ET angesetzt.
Das Unternehmen wird einen Live-Stream der Konferenzpräsentation bereitstellen, der über die Seite 'Veranstaltungen und Präsentationen' im Bereich 'Investoren und Medien' auf der Website von Apellis zugänglich ist. Interessierte, die nicht an der Live-Präsentation teilnehmen können, haben etwa 90 Tage nach der Veranstaltung Zugang zu einer Wiederholung des Webcasts.
- None.
- None.
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET.
The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
FAQ
When is Apellis Pharmaceuticals (APLS) presenting at the TD Cowen Healthcare Conference 2025?
How long will the APLS TD Cowen conference webcast replay be available?
Where can investors watch Apellis' (APLS) TD Cowen conference presentation?
What type of event is APLS participating in on March 3, 2025?
